| Ident. | Authors (with country if any) | Title |
|---|
| 000254 (2015) |
Atsuko Kawaguchi [Japon] ; Toshiyuki Yamamoto [Japon] ; Yukari Okubo [Japon] ; Yoshihiko Mitsuhashi [Japon] ; Ryoji Tsuboi [Japon] | Multiple halo nevi subsequent to a short period of sunbathing |
| 000304 (2013) |
Tomokazu Nagao ; Reina Kusunoki ; Chiaki Iwamura ; Shigeto Kobayashi ; Wako Yumura ; Yosuke Kameoka [Japon] ; Toshinori Nakayama ; Kazuo Suzuki [Japon] | Correlation of interleukin‐6 and monocyte chemotactic protein‐1 concentrations with crescent formation and myeloperoxidase‐specific anti‐neutrophil cytoplasmic antibody titer in SCG/Kj mice by treatment with anti‐interleukin‐6 receptor antibody or mizoribine |
| 000403 (2013) |
S. Momohara [Japon] ; J. Hashimoto ; T. Suguro [Japon] | FRI0204 Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab: Results from the multicentre topp (tocilizumab in perioperative period) study |
| 000540 (2013) |
N. Asai ; T. Kobayakawa ; K. Saito ; T. Shioura ; Y. Yabe [Japon] ; T. Kojima ; A. Kaneko [Japon] ; N. Ishiguro | AB0564 Continuation and remission rates of tocilizumab treatment based on improvement in patient global assessment: 2-year study based on the tsurumai biologics communication registry |
| 000556 (2013) |
Y. Yabe [Japon] ; T. Kojima ; A. Kaneko ; Y. Kanayama ; Y. Hirano ; T. Shioura ; K. Saito [Japon] ; N. Asai ; T. Kobayakawa ; N. Ishiguro | SAT0143 Analysis of Patients Who Obtained Remission by Disease Activity Score After Tocilizumab Treatment But Still had Low Disease Activity by Clinical Disease Activity Index, and Examination of Points for Treatment Intensification |
| 000567 (2013) |
Y. Yabe [Japon] ; T. Kojima ; A. Kaneko ; Y. Kanayama ; Y. Hirano ; T. Shioura ; K. Saito [Japon] ; N. Asai ; T. Kobayakawa ; N. Ishiguro | AB0338 Evaluation of tocilizumab treatment continuation rate stratified by time of start of administration |
| 000572 (2013) |
Y. Yabe [Japon] ; T. Kojima ; A. Kaneko ; Y. Kanayama ; T. Shioura ; N. Asai ; T. Kobayakawa ; K. Saito [Japon] ; N. Ishiguro | AB0590 Rates of treatment continuation and remission in 97 patients with high c-reactive protein receiving tocilizumab: 2-year study based on the tsurumai biologics communication registry |
| 000581 (2013) |
T. Takeuchi [Japon] ; Y. Tanaka ; K. Amano ; J. Kikuchi [Japon] ; E. Tanaka [Japon] ; S. Hirata ; H. Nagasawa ; H. Yasuoka [Japon] ; H. Yamanaka [Japon] | SAT0140 Effectiveness of Abatacept Against Rheumatoid Arthritis in Daily Clinical Practice - Orbit Study |
| 000678 (2013) |
Y. Tanaka ; T. Takeuchi [Japon] ; K. Amano ; E. Sato [Japon] ; M. Nawata ; H. Nagasawa ; D. Hoshi [Japon] ; K. Saito ; S. Fukuyo ; K. Hanami ; H. Kameda [Japon] ; T. Kurasawa ; Y. Kaneko [Japon] ; H. Yamanaka [Japon] | AB0586 104-weeks assessments of clinical and structural remission in rheumatoid arthritis patients with tocilizumab from the reaction study |
| 000763 (2013) |
H. Yamanaka ; M. Harigai ; S. Inokuma [Japon] ; N. Ishiguro ; J. Ryu [Japon] ; S. Takei ; T. Takeuchi [Japon] ; Y. Tanaka ; Y. Sano [Japon] ; T. Koike [Japon] | THU0092 The advantage of early intervention by tocilizumab for rheumatoid arthritis - full analysis of all-case postmarketing surveillance in 7,901 patients in japan |
| 000787 (2013) |
Y. Miwa [Japon] ; H. Furuya [Japon] ; R. Yanai [Japon] ; K. Ohtsuka [Japon] ; M. Sato [Japon] ; R. Takahashi [Japon] ; K. Wakabayashi [Japon] ; N. Yajima [Japon] ; T. Kasama [Japon] ; M. Hosaka [Japon] | AB0447 Comparison of efficacy of four biological agents for rheumatoid arthritis patients using the HRQOL questionnaire and depression scale |
| 000804 (2013) |
T. Takeuchi [Japon] ; Y. Kaneko [Japon] ; T. Atsumi ; Y. Tanaka ; M. Inoh ; H. Kobayashi [Japon] ; K. Amano ; M. Miyata ; Y. Murakawa ; T. Fujii ; A. Kawakami ; H. Yamanaka ; K. Yamamoto ; N. Miyasaka [Japon] ; T. Mimori | OP0040 Adding Tocilizumab or Switching to Tocilizumab Monotherapy in RA Patients with Inadequate Response to Methotrexate: 24-Week Results from a Randomized Controlled Study (Surprise Study) |
| 000890 (2013) |
H. Kobayashi ; I. Yokoe [Japon] ; A. Nishiwaki [Japon] ; H. Sato [Japon] ; Y. Kobayashi [Japon] | OP0313 Effect of Tocilizumab on Left Ventricular Function Assessed Using a Comprehensive Cardiac Magnetic Resonance Approach in Rheumatoid Arthritis Patients without Cardiac Symptoms |
| 000906 (2013) |
N. Nishina [Japon] ; J. Kikuchi [Japon] ; M. Hashizume [Japon] ; K. Yoshimoto [Japon] ; H. Kameda [Japon] ; T. Takeuchi [Japon] | FRI0001 Baseline soluble interleukin-6 receptor levels predict the clinical effectiveness of tocilizumab in patients with rheumatoid arthritis |
| 000999 (2013) |
M. Harigai ; S. Inokuma [Japon] ; N. Ishiguro ; J. Ryu ; T. Takeuchi [Japon] ; S. Takei ; Y. Tanaka ; H. Yamanaka ; Y. Sano [Japon] ; H. Yaguramaki [Japon] ; T. Koike [Japon] | SAT0120 Characteristics Associated with Better Effectiveness and Safety in Rheumatoid Arthritis Patients Treated with Intravenous Tocilizumab: Results from Full Analysis of All-Patient Postmarketing Surveillance in Japan |
| 000A89 (2009) |
Saiko Kurosawa [Japon] ; Nobu Akiyama [Japon] ; Akira Ohwada [Japon] ; Masahiro Warabi [Japon] ; Matsuhiko Suenaga ; Masaru Kojima [Japon] ; Junji Tomiyama [Japon] | Idiopathic Plasmacytic Lymphadenopathy with Polyclonal Hypergammaglobulinemia Accompanied with Cutaneous Involvement and Renal Dysfunction |
| 000B48 (2013) |
T. Matsubara ; K. Okuda ; J. Chiba [Japon] ; A. Takayama [Japon] ; H. Inoue ; T. Sakurai ; H. Wakabayashi ; A. Kaneko ; K. Sugimoto ; H. Yamazaki ; T. Takanashi ; Y. Takasaki [Japon] ; N. Tamura [Japon] ; M. Ogasawara [Japon] ; M. Inoo ; I. Onishi ; S. Kawai [Japon] ; R. Nohara [Japon] | FRI0207 A phase I/II clinical trial of intra-articular administration of ARG098, an anti-FAS IGM monoclonal antibody, in knee joint synovitis of japanese patients with rheumatoid arthritis |
| 000C06 (2013) |
Y. Tanaka ; M. Harigai ; T. Takeuchi ; H. Yamanaka [Japon] ; N. Ishiguro ; K. Yamamoto [Japon] ; M. Kanazawa ; Y. Murakami ; T. Yoshinari [Japon] ; D. Baker [États-Unis] ; N. Miyasaka ; T. Koike [Japon] | FRI0177 52-week results of clinical, radiographic and pharmacokinetic assessments: Golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks in patients with active rheumatoid arthritis despite methotrexate therapy |
| 000C84 (2013) |
Y. Tanaka ; K. Yamamoto [Japon] ; T. Takeuchi ; H. Yamanaka [Japon] ; N. Ishiguro ; K. Eguchi ; A. Watanabe [Japon] ; H. Origasa ; T. Okamoto ; T. Shoji ; N. Miyasaka [Japon] ; T. Koike [Japon] | AB0294 Long-term comprehensive disease control with certolizumab pegol regardless of concomitant dmards: results from the japanese cohort |
| 000E02 (2013) |
Y. Miwa [Japon] ; S. Isojima [Japon] ; M. Umemura [Japon] ; H. Tsukamoto [Japon] ; T. Tokunaga [Japon] ; H. Furuya [Japon] ; R. Yanai [Japon] ; K. Otsuka [Japon] ; R. Takahashi [Japon] ; K. Wakabayashi [Japon] ; N. Yajima [Japon] ; T. Kasama [Japon] ; M. Hosaka [Japon] | AB0200 Switching biologic agents in patients with rheumatoid arthritis: an observational study of 159 patients evaluating efficacy, adl, qol, and depression |
| 000F67 (2013) |
Y. Miwa [Japon] ; S. Isojima [Japon] ; M. Umemura [Japon] ; H. Tsukamoto [Japon] ; T. Tokunaga [Japon] ; H. Furuya [Japon] ; R. Yanai [Japon] ; K. Otsuka [Japon] ; R. Takahashi [Japon] ; K. Wakabayashi [Japon] ; N. Yajima [Japon] ; T. Kasama [Japon] ; M. Hosaka [Japon] | AB0263 Correlation of cx3cl1 levels with adl, hrqol and depression to biologic agent therapy in patients with rheumatoid arthritis |
